RRx-001 [CAS 925206-65-1]

RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].

[925206-65-1]

C5H6BrN3O5

268.02

BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O

Apoptosis; CD47; Parasite

Plasmodium

10mM

99.79

DMSO : ≥ 100 mg/mL

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H301, H311, H331, H341

H301, H311, H331, H341